RGBP Shares at Bargain Basement Prices
REGEN BIOPHARMA, INC.
RGBP Shares at Bargain Basement Prices
Rob Goldman
August 22, 2025
REGEN BIOPHARMA, INC. (OTC: RGBP: $0.026)
Industry: BioPharma
COMPANY SNAPSHOT
Regen BioPharma, Inc. is focused on the immunology and immunotherapy spaces. The Company seeks to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, Regen has one cleared Investigational New Drug Application and 2 others pending FDA approval.
KEY STATISTICS
- Price as of 8/21/25$0.026
- 52 Wk High – Low$0.27 – $0.02
- Est. Shares Outstanding33.5M
- Market Capitalization$1.0M
- Average Volume204,377
- Exchange:OTCID
COMPANY INFORMATION
Regen BioPharma, Inc.
4700 Spring Street
Suite 304
La Mesa CA 91942
Web: www.RegenBiopharmaInc.com
Email: david.koos@regenbiopharma.com
Phone : 619.722.5505
INVESTMENT HIGHLIGHTS
The Bottom Line: There are times when stocks trade irrationally, creating rare opportunities. Regen BioPharma is a perfect example of such a situation. In our view, Regen’s share price is a terrific entry point, and we believe opportunistic traders and investors could be enviable beneficiaries of substantial, higher price action, ahead.
The Background: We published an updated report on Regen on July 17, 2025. The previous closing price was $0.04989 and it more than doubled in just a few days on strong volume. It even broke through its 50 and 200 DMAs. Since then, a legacy holder (presumably) appears to have been an indiscriminate seller. We believe this is a short-term blip rather than a long-term trend.
Ridiculously Oversold: In these instances, sellers do not care for fundamentals, valuation, or prospects. In the case of RGBP, that is a gross miscalculation. Just a month ago, these shares were over $0.11 and valued at around $4M, which quite frankly was still far below our target price and our sentiment regarding present-day valuation. Today, the valuation is sharply lower despite the fact that Regen is migrating from the preclinical stage to the clinical stage. We believe it should enjoy the valuation in which it was afforded at its recent peak.
Don’t Forget…: Fundamentally, the wind is at Regen’s back. The Company is on track to raise funds for the Phase I clinical trial and investors in such a transaction would likely be in for the long haul, given the upside inherent in the Regen story. Given these and other factors, we reiterate our price $0.30 price target.
Senior Analyst: Robert Goldman
Rob Goldman founded Goldman Small Cap Research in 2009 and has over 25 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell side analyst, Rob was a senior member of Piper Jaffray’s Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.’s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund.
Analyst Certification
I, Robert Goldman, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report.
Disclaimer
This Opportunity Research report was prepared for informational purposes only.
Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select format reflects the Firm’s internally generated stock ideas along with economic and stock market outlooks. Opportunity Research reports, updates and Microcap Hot Topics articles reflect sponsored (paid) research but can also include non-sponsored micro-cap research ideas that typically carry greater risks than those stocks covered in the Select Research category. It is important to note that while we may track performance separately, we utilize many of the same coverage criteria in determining coverage of all stocks in both research formats. Research reports on profiled stocks in the Opportunity Research format typically have a higher risk profile and may offer greater upside. During 2023, Goldman Small Cap Research was compensated by a third party in the amount of $5000 for research reports and a press release. In July 2025, Goldman Small Cap Research was compensated $5000 for this research report and a press release. In July 2025, Goldman Small Cap Research was not compensated for a research update. In August 2025, Goldman Small Cap Research was compensated $5500 for research content production and content distribution. All information contained in this report was provided by the Company via filings, press releases or its website, or through our own due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.
Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.
Separate from the factual content of our articles about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Such information and the opinions expressed are subject to change without notice.
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. This report does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.
ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.
For more information, visit our Disclaimer: www.goldmanresearch.com